GlobalData on MSN1d
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEFThe trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...
In addition to tirzepatide’s application in obesity and type 2 diabetes (T2D), it is also in pre-registration for obstructive ...
Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
Payers and employers have tightened access to the glucagon-like peptide 1 receptor agonist class once these therapies became ...
The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating the ...
News Medical on MSN1d
Tirzepatide lowered risk of worsening heart failure and CVD death for obese adultsIn the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...
Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback